Clindamycin-d3 is intended for use as an internal standard for the quantification of clindamycin by GC- or LC-MS. Clindamycin is a lincosamide antibiotic.1,2 It is active against Gram-positive bacteria, including various strains of S. pneumoniae, S. viridans, S. aureus, and S. epidermidis (MICs = 0.002-0.1, 0.005-0.2, 0.04-1.6, and 0.1-0.2 µg/ml, respectively).1 Clindamycin is also active against chloroquine-resistant and -sensitive strains of P. falciparum (IC50s = 3.12 and 8.81 nM, respectively).2 It inhibits bacterial protein synthesis by interacting with the 50S ribosome.1 Clindamycin increases survival in a mouse model of a secondary S. pneumoniae infection when administered at a dose of 15 mg/kg twice daily for seven days.3 Formulations containing clindamycin have been used in the treatment of bacterial infections.
1.SpÍ?ek, J., and ?ezanka, T.Lincomycin, clindamycin and their applicationsAppl. Microbiol. Biotechnol.64(4)455-464(2004) 2.Dahl, E.L., and Rosenthal, P.J.Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplastAntimicrob. Agents Chemother.51(10)3485-3490(2007) 3.KarlstrÖm, Å., Boyd, K.L., English, B.K., et al.Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenzaJ. Infect. Dis.199(3)311-319(2009)